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Key points:  
- Case validation of acute liver injury (ALI) was conducted in two Spanish 
databases, EpiChron and SIDIAP, and in the Danish national registers.  
- Validation of potential cases included patient profiles review and adjudication 
based on clinical data extracted from medical records.  
- The overall PPVs obtained were higher for specific than for nonspecific codes 
and for hospital discharge than for outpatient codes.  
- The nonspecific code “unspecified jaundice” had high PPVs for all ALI 
definitions in the Denmark but not in the Spanish databases. 
- To maximize validity, studies on ALI should prioritize hospital specific discharge 
codes.   
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Abstract   
Background: Validating cases of acute liver injury (ALI) in automated health data sources 
is challenging. Positive predictive values (PPVs) have been <60% in previous validation 
studies, except in one that reported PPVs >75%. Thus, we aimed to determine the ability of 
three ALI definitions to correctly identify ALI cases in three automated health care data 
sources. 
Methods: Case validation was undertaken in a study conducted from 2009 to 2014 
assessing the risk of ALI in users of antidepressants in databases in Spain (EpiChron and 
SIDIAP) and the Danish National Health Registers. Three ALI definition algorithms 
definitions were evaluated: primary (specific hospital discharge codes), secondary (specific 
and nonspecific hospital discharge codes), and tertiary (specific and nonspecific hospital 
and outpatient codes). The validation strategy included: review of patient profiles in 
EpiChron and SIDIAP and of clinical data abstracted from medical records in EpiChron 
and Denmark. ALI cases were considered confirmed when liver enzyme values met a 
definition by an international working group. 
Results: Overall PPVs (95% CIs) for the algorithms used to identify potential cases of the 
study ALI definitions were, for the primary ALI definition, 84% (60%-97%) (EpiChron), 
60% (26%-88%) (SIDIAP), and 74% (60%-85%) (Denmark); for the secondary ALI 
definition, 65% (45%-81%) (EpiChron), 40% (19%-64%) (SIDIAP), and 70% (64%-77%) 
(Denmark); and for the tertiary ALI definition, 25% (18%-34%) (EpiChron), 8% (7%-9%) 
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(SIDIAP), and 47% (42%-52%) (Denmark). The overall PPVs were higher for specific than 
for nonspecific codes and for hospital discharge than for outpatient codes. The nonspecific 
code “unspecified jaundice” had high PPVs for all ALI definitions in Denmark. 
Conclusions: PPVs obtained apply to patients using antidepressants without preexisting 
liver disease or risk factors for ALI. To maximize validity, studies on ALI should prioritize 
hospital specific discharge codes and should include hospital codes for unspecified 
jaundice. Case validation is required when ALI outpatient cases are considered.  
6 
Introduction  1 
Acute liver injury (ALI) is defined as a sudden appearance of liver test abnormalities and 2 
includes a broad spectrum of clinical scenarios, ranging from mild abnormal biochemical 3 
liver values to acute liver failure.1,2  4 
Previous validation studies have shown that identification of potential ALI events through 5 
diagnosis and procedural codes is challenging and that most validated algorithms have 6 
positive predictive values (PPVs) below 60%,3-5 except in one study, which reported PPVs 7 
>75%.6 All previous studies highlight the need for validation by medical record review 8 
when conducting studies of ALI based on automated health care data sources. This is 9 
especially important in drug safety studies, in which reliance on algorithms alone for 10 
automated case identification will most likely result in misclassification and overestimation 11 
of the true incidence of ALI and biased effect estimates. 12 
As part of a recent post-authorization safety study (PASS) conducted in five European data 13 
sources investigating the potential risk of ALI associated with the use of agomelatine and 14 
nine other antidepressant drugs,7 validation of the algorithms used to identify ALI cases 15 
was conducted. This was done via medical record review in three of those data sources: two 16 
Spanish health care databases and the Danish National Health Registers.  17 
7 
Methods 18 
The objective of this study was to determine the ability of two ALI definitions to correctly 19 
identify ALI cases in an automated health care data source in the context of a PASS but also 20 
for future studies. Specifically, we aimed to validate the following:  21 
 An ALI definition including only main hospital discharge diagnosis codes 22 
 An ALI definition including main hospital discharge and also outpatient diagnosis 23 
codes  24 
In addition, within each definition, we evaluated the ways in which the specific and 25 
nonspecific codes differed in validity. 26 
Study setting 27 
Five automated health care databases were used in the agomelatine PASS.7 Three of these 28 
in two countries were used to conduct a validation study: in Spain, the EpiChron cohort 29 
from Aragon Health Sciences Institute (Aragón, Spain)8 and the Information System for 30 
Research in Primary Care (SIDIAP) (Catalonia, Spain)9; and in Denmark, the Danish 31 
National Health Registers (Denmark).10,11 The main characteristics of each database are 32 
included in Supplementary eTable 1. Of the two databases that were not used, validation by 33 
review of medical records is not an option in the German Pharmacoepidemiological 34 
Research Database (GePaRD) (Germany)12-14 and was not feasible within the study 35 
timeframe in the Swedish National Registers (Sweden).15,16 Nevertheless, an external 36 
validation study was conducted in Germany,17 the results of which will be presented in a 37 
separate publication.  38 
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Identification and definition of ALI 39 
Cases of ALI were identified in cohorts of new users of the ten study antidepressants 40 
evaluated in the agomelatine PASS study between 2009 and 20147: citalopram, 41 
agomelatine, fluoxetine, paroxetine, sertraline, escitalopram, duloxetine, venlafaxine, 42 
mirtazapine, and amitriptyline. Individuals aged 18 years or older at the date of their first-43 
recorded prescription fill of any of the study antidepressants during the study period(s) 44 
entered the cohort if they (1) had not received a prescription fill for the same study 45 
antidepressant within the prior 12 months (new users) and (2) had at least 12 months of 46 
continuous enrolment in the data source before the first prescription fill. Absence of 47 
pregnancy at the start date of antidepressant use was an additional inclusion criterion for 48 
women. Patients with a history of liver disease or risk factors for liver disease (e.g., alcohol 49 
and drug abuse and dependence-related disorders), chronic biliary or pancreatic disease, 50 
malignancy, or other life-threatening conditions (e.g., HIV infection) were excluded from 51 
the study cohort (Supplementary eMethods). 52 
Three algorithms corresponding to three endpoint definitions were used in the agomelatine 53 
PASS to automatically identify potential ALI cases based on diagnosis codes (Table 1).7,18 54 
These definitions include combinations of codes that have shown higher (specific) or lower 55 
(nonspecific) PPVs in previous studies.3-6 The primary ALI definition was defined as any 56 
patient with a specific main hospital discharge diagnosis code of ALI from either the 57 
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-58 
CM) or the International Statistical Classification of Diseases and Related Health 59 
Problems, Tenth Revision (ICD-100) (Table 2). The primary ALI definition was not 60 
9 
validated per se, but the specific codes identifying the primary ALI definition were 61 
included in the secondary ALI definition, which underwent validation. The algorithm used 62 
to identify potential cases of the secondary study ALI definition was defined as any patient 63 
with a hospital main specific or nonspecific discharge code (ICD-9-CM or ICD-10) for 64 
ALI. Finally, the algorithm for the tertiary ALI definition was assessed using specific and 65 
nonspecific codes from either ICD-9-CM or ICD-10 identified in both hospital and 66 
outpatient settings. In EpiChron, International Classification of Primary Care (ICPC) codes 67 
were used to identify outpatient cases of the tertiary ALI definition and ICD-9-CM to 68 
identify hospital cases. In SIDIAP, ICD-10-CM was used to identify primary care 69 
diagnoses and ICD-9-CM to identify hospital cases. In Denmark, primary care codes were 70 
not available and therefore only hospital ICD-10 codes were used both for case 71 
identification and to apply exclusion criteria. The interplay between the three ALI 72 
definitions is displayed in Figure 1.  73 
[Add Table 1 and Figure 1 here] 74 
Diagnostic criteria for ALI 75 
Potential cases of ALI identified with the electronic algorithms and reviewed by 76 
adjudicators were considered confirmed (true positives)19 if any of the following three 77 
qualifying criteria for increases in serum levels with <1 year of persistence were met 78 
(aspartate transaminase [AST] levels could be used instead of ALT levels only if ALT 79 
levels were unavailable and there was no known muscle pathology driving the rise in AST):  80 
 ≥ 5 x upper limit of normal (ULN) alanine aminotransferase (ALT)  81 
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 ≥ 2 x ULN alkaline phosphatase (ALP) 82 
 ≥ 3 x ULN ALT and > 2 x ULN bilirubin 83 
The requirement of less than 1 year of persistence of the liver function test abnormalities 84 
was introduced to ensure that cases had ALI and not chronic liver injury.19 This criterion 85 
was evaluated using the most recent liver enzymes results from the period 12 to 24 months 86 
before the index date to check whether they were not elevated beyond 10% of the ULN (if 87 
no results were available, the criterion was considered as met). 88 
A false-positive case of ALI was defined as a potential case with enough data to be 89 
evaluated but that did not meet the criteria to be classified as a confirmed case of ALI. A 90 
non-evaluable case of ALI was defined as a potential case that lacked some of the required 91 
liver enzyme results to be evaluated. 92 
Validation steps 93 
The strategy for validating potential cases identified by automated algorithms across the three 94 
data sources included up to three steps: review of patient profiles (which is a deidentified 95 
chronological listing of medical events and drug prescriptions and is used to detect exclusion 96 
diagnoses missed by the electronic algorithm and to provide an initial assignment of case 97 
status), medical record abstraction of relevant clinical data by trained health care 98 
professionals, and review of abstracted data and case adjudication by trained physicians. 99 
However, local adaptations were required in Denmark and SIDIAP to reflect data availability 100 
and/or local regulations (Supplementary eTable 2). In Denmark, patient profiles were not 101 
reviewed due to the very limited clinical information available. Also, primary care data were 102 
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not available. Finally, patients with study exclusion criteria not identified by hospital codes 103 
were excluded during either the abstraction or the review of the abstracted information from 104 
medical records. In SIDIAP, source hospital medical records were not accessible; therefore, 105 
patient profile review relied only on liver enzyme results available from primary care and 106 
yielded the final case classifications in this database. Cases were reviewed both by trained 107 
physicians for all secondary ALI definition potential cases and by an electronic algorithm for 108 
the tertiary ALI definition due to the large number of identified potential cases.  109 
Several quality control checks and measures were performed. All the health care 110 
professionals at each site involved in the validation, including nurses, clinical pharmacists 111 
and physicians, received training on the validation processes. In EpiChron, for quality 112 
control purposes, patient profiles of a random sample of ten potential cases were reviewed 113 
independently by a second physician and a random sample of 25% of the confirmed cases 114 
and of ten inpatient non-evaluable cases also were reviewed by a second physician. In 115 
SIDIAP, for the tertiary ALI definition, an electronic algorithm evaluated all potential cases 116 
and 10% of them were also evaluated manually by trained professionals blinded to the 117 
study exposure. A very high level of agreement (kappa statistic equal to or larger than 0.95) 118 
between the algorithm and the manual reviewers was obtained before the algorithm was 119 
generalized; agreement between the two clinician reviewers was also assessed (kappa 120 
statistic = 1). Similarly, in Denmark, an algorithm was created to evaluate potential cases. 121 
Trained physicians manually reviewed 50 potential cases, all of which were also reviewed 122 
using the automated algorithm. All potential cases were evaluated using the automated 123 
algorithm only after the kappa measuring the agreement between manual review and the 124 
algorithm reached 1.  125 
12 
Statistical analyses 126 
Validity of the electronic algorithms and individual codes used to identify potential cases of 127 
ALI for the secondary and tertiary ALI definitions  was assessed by calculating the overall 128 
PPV of the algorithm, the overall PPVs of the specific and nonspecific codes, and the PPV 129 
of each individual code. PPVs for the primary ALI definition were indirectly calculated 130 
through the specific codes of the secondary ALI definition. The PPV was calculated as true 131 
positives/(true positives + false positives). In a sensitivity analysis, non-evaluable cases 132 
were included in the PPV denominator.  133 
The PPVs were computed with 95% confidence intervals (CIs) for binomial proportions by 134 
the exact method using Stata software20—version 12 at EpiChron and version 14 at 135 
Denmark. At SIDIAP, SAS statistical software (version 9.4; SAS Institute, Inc; Cary, North 136 
Carolina) and R software version 3.3.1 were used. 137 
Results  138 
The number of users of antidepressants and the final number of new users (after applying 139 
inclusion/exclusion criteria) in the three databases in which validation of potential cases 140 
was conducted are included Supplementary eTable 3. In EpiChron, SIDIAP, and Denmark, 141 
59, 34, and 489 potential cases of the secondary ALI definition, respectively, were 142 
identified; and 268, 2,826, and 1,008 potential cases of the tertiary ALI definition were 143 
identified. Then, 31, 20, and 213 potential cases of the secondary ALI definition were 144 
considered evaluable cases; and 134, 2,242, and 443 potential cases of the tertiary ALI 145 
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definition were considered evaluable cases. Of them, 20, 8, and 150 cases of the secondary 146 
ALI definition and 34, 172, and 208 cases of the tertiary ALI definition were confirmed 147 
(true positives) after validation (Figure 2). 148 
[Add Figure 2 here] 149 
Regarding the tertiary ALI definition, which includes the total number of cases for all ALI 150 
definitions (see Figure 1), more than 70% of true positives in Denmark and SIDIAP and 151 
56% of true positives in EpiChron were females. Overall, the age group with the highest 152 
number of true positives was patients 80 years and older, followed by patients aged 50 to 153 
79 years (Supplementary eTable 4).   154 
The overall PPVs for the algorithm used to identify potential cases of the secondary ALI 155 
definition were 65% (95% CI, 45%-81%) in EpiChron, 40% (95% CI, 19%-64%) in 156 
SIDIAP, and 70% (95% CI, 64%-77%) in Denmark (Table 2). As discussed in the Methods 157 
section, the primary ALI definition was indirectly validated through the specific hospital 158 
discharge codes used in the secondary ALI definition, for which the overall PPVs were 159 
84% (95% CI, 60%-97%) in EpiChron, 60% (95% CI, 26%-88%) in SIDIAP, and 74% 160 
(95% CI, 60%-85%) in Denmark. The overall PPVs for the specific codes were higher than 161 
those for the nonspecific codes in all data sources (Table 2). In EpiChron and SIDIAP, the 162 
individual specific code 570.x (acute and subacute necrosis of liver) had the highest PPV, 163 
while the code 573.3 (hepatitis unspecified) captured the highest proportion of true 164 
positives (Table 3). In Denmark, the individual specific codes K71.2 (toxic liver disease 165 
with acute hepatitis) and K71.6 (toxic liver disease with hepatitis, not elsewhere specified) 166 
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obtained the highest PPVs and captured the highest proportion of true positives (Table 4). 167 
None of the nonspecific codes captured more than two true positives in EpiChron and 168 
SIDIAP (Table 3). Conversely, in Denmark, the individual nonspecific code R17 169 
(unspecified jaundice, excludes neonatal) contributed the largest number of true positives 170 
and had the highest PPV among all individual specific or nonspecific hospital discharge 171 
codes.  172 
[Add Tables 2 and 3 here] 173 
For the tertiary ALI definition, the overall PPVs were 25% (95% CI, 18%-34%) in 174 
EpiChron, 8% (95% CI, 7%-9%) in SIDIAP, and 47% (95% CI, 42%-52%) in Denmark. 175 
As observed for the secondary ALI definition, we observed higher PPVs for specific than 176 
nonspecific codes in all data sources (Table 2). Among the individual specific codes, 570.x 177 
(acute and subacute necrosis of liver) had the highest PPV in EpiChron and SIDIAP (Table 178 
3 and Supplementary eTable 5). In Denmark, code K71.2 (toxic liver disease with acute 179 
hepatitis) had the highest PPV among specific codes (Table 4). Among the nonspecific 180 
codes, 782.4 (jaundice, unspecified, not of newborn) had the highest PPV in both EpiChron 181 
and SIDIAP, although it had a low number of confirmed cases (one and two true positives 182 
in EpiChron and SIDIAP, respectively). In Denmark, ICD-10 code R17 (unspecified 183 
jaundice, excludes neonatal) had the highest PPV (91%) and contributed the largest number 184 
of true positives. In SIDIAP, the same code used to identify primary care diagnoses had the 185 
second highest PPV, and it was also the second highest contributor of true positives. 186 
Regarding code R74.0 (nonspecific elevation of transaminase or LDH), it was the code 187 
with the highest number of true positives, although it had a low PPV (6%). 188 
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[Add Table 4 here] 189 
In the sensitivity analysis including non-evaluable cases in the denominator of the PPV 190 
calculation, the overall PPVs for all study ALI definitions and for both specific and 191 
nonspecific codes were smaller than those for the main PPV analysis in all data sources 192 
(see Supplementary eTables 6 and 7).  193 
Discussion  194 
We observed consistently higher overall PPVs for specific ALI codes versus nonspecific 195 
codes and higher overall PPVs for hospital discharge codes versus outpatient codes. The 196 
identification of ALI cases based on hospital discharge specific codes, considered as the 197 
primary ALI definition in this study, resulted in higher PPVs when compared with most 198 
previously described algorithms.3-6   199 
In contrast to the present study, previous studies conducted to validate ALI cases have 200 
reported PPVs below 60%,3-5 or around 75%.6 A recently published systematic review and 201 
meta-analysis including 29 studies validating drug-induced liver injury (DILI) (25 of them 202 
presenting PPVs) showed a pooled PPV estimate of 14.6% (95% CI, 10.7-18.9), with PPVs 203 
ranging from 1.0% to 40.2%.21 The authors of that study suggested that the low PPVs 204 
observed in the studies might be explained by the low prevalence of DILI. In addition, a 205 
different list of diagnosis codes, laboratory threshold criteria, and study drugs might be the 206 
cause of the differences between studies. When we compared our study with previous 207 
studies validating ALI definitions, we observed that our study differed from these previous 208 
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studies in different ways: Bui et al.6 did not exclude patients with hepatic, biliary, or 209 
pancreatic diseases or cancer; Lo Re et al.3 included only cases of severe ALI; Udo et al. 5 210 
validated cases of idiopathic ALI only; and Traversa et al.4 validated cases of ALI 211 
associated with the use of nonsteroidal anti-inflammatory drugs. In addition, there are 212 
differences in the type of data sources: the Bui et al.6 and Lo Re et al.3 studies were 213 
conducted in claims databases including inpatient and outpatient encounters, prescriptions, 214 
and laboratory tests. The Traversa et al.4 and Udo et al.5 studies were conducted in hospital 215 
databases in a way similar to the Danish component of our study. There are also differences 216 
in the ALI definition used in previous studies compared with the criteria used in our study, 217 
which were based on Aithal criteria.19 Finally, the list of codes included in the present study 218 
was also different compared with those in previous studies.  219 
Positive predictive values obtained in the present study for the ICD-9 specific codes 573.3 220 
(hepatitis unspecified) and 570.x (acute and subacute necrosis of liver) and specific ICD-10 221 
codes K71.2 (toxic liver disease with acute hepatitis) and K71.6 (toxic liver disease with 222 
hepatitis, not elsewhere specified) were in line with previous studies. In Udo et al.,5 the 223 
code 573.3 had a PPV of 80%. In Bui et al.,6 the PPV for individual code 570.x was 84% 224 
and for 573.3 was 76%, while the PPV for the algorithm including codes 570.x, 572.2 225 
(hepatic coma), or 573.3 was 74%. In Lo Re et al.,3 the PPVs for individual codes ranged 226 
from 6.5% to 54.3%, the combination of codes 570.x with 572.8 (sequelae of liver disease; 227 
hepatic failure) had a PPV of 100%, and code 570.x in combination with 572.2 had a PPV 228 
of 67%. In addition, the authors calculated PPVs including patients with preexisting liver 229 
disease, and the PPVs were higher when compared with the subset of the population that 230 
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excluded those patients.3 In two studies validating drug-induced ALI (DILI),22,23 code 573.3 231 
(hepatitis unspecified) was the highest contributor of DILI cases.  232 
In the present study, the nonspecific code for unspecified jaundice (R17) obtained high 233 
PPVs, and it was the highest contributor of true positives in Denmark. In EpiChron and 234 
SIDIAP databases, the ICD-9-CM code 782.4 (jaundice, unspecified, not of newborn) had 235 
high PPVs for the secondary ALI definition (hospitalized cases), although the number of 236 
true positives was one and two cases, respectively. In SIDIAP, the ICD-10 code for 237 
unspecified jaundice used in the tertiary ALI definition to validate hospitalized and 238 
outpatient cases was the second contributor of true positives and had the second-highest 239 
PPV, although it was low (35%). Potential explanations for this discrepancy in the results 240 
for unspecified jaundice code between Denmark and Spanish data sources could be the 241 
following: (1) in Denmark, only hospitalized and outpatient cases from hospital outpatient 242 
clinics are validated; and (2) in Denmark, exclusion criteria not identified previously were 243 
applied, if identified, during either the abstraction or the review of the abstracted 244 
information from medical records. These reasons may reduce the presence of false positives 245 
and justify the high PPV observed for this code in Denmark compared with Spanish data 246 
sources. Results observed in Denmark also contrast with those in a previous study,23 which 247 
reported that the nonspecified code for unspecified jaundice identified only a small 248 
proportion of DILI cases (5% of the 265 cases in Shin et al.23 vs. 39% of the 208 cases of 249 
the tertiary ALI definition confirmed in Denmark observed in our study), but the 250 
differences when validating ALI or DILI cases must be taken into account. In addition, the 251 
study by Shin et al.23 was not restricted to hospital cases as it was in Denmark, where the 252 
18 
prevalence of true ALI among outpatient primary care cases must be lower, which would 253 
explain the differences observed between the two studies.  254 
Strengths and Limitations 255 
In terms of number of validated cases, the present validation study represents one of the 256 
largest efforts performed in Europe to validate ALI cases identified in automated health 257 
care databases, using case-identifying algorithms, and confirmed according to consensus 258 
criteria based on the presence of elevated liver enzyme levels in blood. In addition, this 259 
study is the first to validate ICD-10 codes related to ALI. However, the results obtained in 260 
the present study must be evaluated in the context of its limitations. An important limitation 261 
of this study is that, although the ALI definitions were consistent across data sources and 262 
based on blood liver enzyme levels, the approach to the evaluation of potential cases was 263 
adapted to the type of information and local resources available for the validation efforts, 264 
which may have impacted our findings. In SIDIAP, the validation was partial for all 265 
potential cases (inpatient and outpatient), based only on liver enzyme results from primary 266 
care, and no hospital medical records to validate hospital cases were available. That could 267 
explain the lowest PPV for the secondary ALI definition in SIDIAP. In Denmark, only 268 
outpatient potential cases from hospital outpatient clinics could be identified (primary care 269 
data were not available). This is probably the reason why the difference in PPVs between 270 
specific and nonspecific codes was smaller in Denmark than in the other data sources, and 271 
it would also explain the higher PPVs obtained in Denmark for the secondary and tertiary 272 
ALI definitions compared with the two Spanish data sources. For some codes, the number 273 
of cases was low, resulting in wide CIs for the PPV. The present study has also other 274 
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limitations. First, we did not conduct validation of false positives, and therefore negative 275 
predictive values could not be estimated. Second, the PPVs obtained in the present study 276 
apply only to patients using the study antidepressant drugs who did not have preexisting 277 
liver disease or risk factors for developing ALI. Third, PPVs are dependent on the ALI case 278 
definition used. In the present study, we used the definition created by Aithal et al.,19 but 279 
there are other case definitions that could be used24,25 and PPVs could have been different 280 
with those other case definition criteria. Finally, PPVs are dependent on ALI prevalence. 281 
Therefore, the PPVs observed in our study might not apply directly to patient populations 282 
with characteristics different from those included in the present study or to studies using 283 
different case definitions.  284 
Conclusions 285 
The PPVs obtained in this study apply to patients using antidepressants without preexisting 286 
liver disease or risk factors for ALI. Future studies evaluating ALI in these and similar data 287 
sources should prioritize use of hospital discharge and specific codes to maximize validity. 288 
Moreover, case-identifying algorithms should include hospital ICD codes for unspecified 289 
jaundice. In studies including nonspecific codes and outpatient cases, case validation is 290 
essential.  291 
 292 
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Tables 
Table 1. ICD-9-CM and ICD-10 Codes Relevant to Acute Liver Injury 
Code Description 
Specific codes  
ICD-9-CM   
570.x Acute and subacute necrosis of liver 
572.2 Hepatic coma 
573.3 Hepatitis unspecified 
ICD-10   
K71.0 Toxic liver disease with cholestasis  
K71.1 Toxic liver disease with hepatic necrosis  
K71.2 Toxic liver disease with acute hepatitis 
K71.6 Toxic liver disease with hepatitis, not elsewhere classified 
K71.9 Toxic liver disease, unspecified 
K72.0 Acute and subacute hepatic failure  
K72.9 Hepatic failure, unspecified 
K75.9 Inflammatory liver disease, unspecified 
K76.2 Central hemorrhagic necrosis of liver 
Nonspecific codes 
ICD-9-CM   
573.8 Other specified disorders of liver 
573.9 Unspecified disorders of liver 
782.4 Jaundice, unspecified, not of newborn 
V42.7 Liver transplant 
790.4 Nonspecific elevation of transaminase or lactic acid dehydrogenase 
789.1 Hepatomegaly 
ICD-10   
K76.8 Other specified diseases of liver 
K76.9 Liver disease, unspecified 
R17 Unspecified jaundice, excludes neonatal 
R16.0 Hepatomegaly, not elsewhere classified 
R16.2 Hepatomegaly with splenomegaly, not elsewhere classified 
29 
Code Description 
R74.0 Nonspecific elevation of transaminase and lactic acid dehydrogenase 
Z94.4 Liver transplant 
ICPC  
D97 Liver disease (specified or unspecified) 
D13 Jaundice 
D23 Hepatomegaly 
A91 Abnormal results investigations 
ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification; 
ICD-10 = International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; 
ICPC = International Classification of Primary Care. 
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Table 2. Positive Predictive Values (PPVs) of Study ALI Definitions and of Overall Specific and Nonspecific 
Codes Used to Identify Potential Acute Liver Injury (ALI) Cases (Non-evaluable Cases Not Included) 
 EpiChron SIDIAP Denmark 
Totala TP PPV, % (95% CI)b Totala TP PPV, % (95% CI)b Totala TP PPV, % (95% CI)b 
Secondary ALI 
definitionc 
31 20 64.5 (45.4-80.8) 20 8 40.0 (19.1-63.9) 213 150 70.4 (63.8-76.5) 
Specific codesd  19 16 84.2 (60.4-96.6) 10 6 60.0 (26.2-87.8) 50 37 74.0 (59.7-85.4) 
Nonspecific codes 12 4 33.3 (9.9-65.1) 10 2 20.0 (2.5-55.6) 163 113 69.3 (61.6-76.3) 
Tertiary ALI definition 134 34 25.4 (18.3-33.6) 2,242 172 7.7 (6.6-8.9) 443 208 47.0 (42.2-51.7) 
Specific codes  18 15 83.3 (58.6-96.4) 46 16 34.8 (21.4-50.2) 73 50 68.5 (56.6-78.9) 
Nonspecific codes 116 19 16.4 (10.2-24.4) 2,196 156 7.1 (6.1-8.3) 370 158 42.7 (37.6-47.9) 
CI = confidence interval; SIDIAP = Information System for Research in Primary Care; TP = true positives. 
a Total of evaluable cases. Non-evaluable cases for the secondary and tertiary ALI definitions were 9 and 104 in EpiChron, 14 and 584 in SIDIAP, and 28 
and 66 in Denmark. 
b PPV was calculated as PPV = confirmed cases / (true positives + false positives). Results are presented as positive predictive values (%) and their 95% 
CIs. 
c The number of cases of the secondary ALI definition with specific codes did not necessarily match the number of cases for the primary ALI definition 
because, for example, a case qualifying as a primary ALI definition with a specific code could also qualify as a secondary ALI definition with a nonspecific 
code. If the latter scenario happened first, for the secondary ALI definition, this case would be computed in the nonspecific codes group rather than in the 
specific codes group. 
31 
d Equivalent to the PPVs for the study primary ALI definition (specific hospital discharge codes).   
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Table 3. Positive Predictive Values (PPVs) of Specific and Nonspecific Codes 
Used to Identify Potential Acute Liver Injury (ALI) Cases: Secondary (Regular 
Font) and Tertiary (Italics) ALI Definitions in Data Sources Using ICD-9-CM 
Codes (Non-evaluable Cases Not Included)a 
 
EpiChron SIDIAP 
Total TP 
PPV, % 
(95% CI)b Total TP 
PPV, % 
(95% CI)b 
Specific codes    
570.x Acute and subacute necrosis of liver      
Secondary ALI definition 5 5 100.0  
(47.82-100.0) 
3 3 100.0  
(29.2-100.0) 
Tertiary ALI definition 5 5 100.0  
(47.8-100.0) 
1 1 100.0  
(2.5-100.0) 
572.2 Hepatic coma        
Secondary ALI definition 1 0 0.0 (0.0-97.5) 0 - - 
Tertiary ALI definition 1 0 0 (0-97.5) 0 - - 
573.3 Hepatitis unspecified        
Secondary ALI definition 13 11 84.6  
(54.6-98.1) 
7 3 42.9  
(9.9-81.6) 
Tertiary ALI definition 12 10 83.3  
(51.6-97.9) 
4 3 75.0  
(19.4-99.4) 
Nonspecific codes    
573.8 Other specified disorders of liver    
Secondary ALI definition 9 2 22.2  
(2.8-60.0) 
6 0 0.0  
(0.0-45.9) 
Tertiary ALI definition 9 2 22.2  
(2.8-60.0) 
5 0 0.0  
(0.0-52.2) 
573.9 Unspecified disorders of liver      
Secondary ALI definition 1 0 0.0 (0.0-97.5) 0 0 - 
Tertiary ALI definition 0 0 - 0 0 - 
782.4 Jaundice, unspecified, not of newborn     
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EpiChron SIDIAP 
Total TP 
PPV, % 
(95% CI)b Total TP 
PPV, % 
(95% CI)b 
Secondary ALI definition 1 1 100  
(2.5-100) 
2 2 100  
(15.8-100) 
Tertiary ALI definition 1 1 100  
(2.5-100) 
2 2 100  
(15.8-100) 
V42.7 Liver transplant        
Secondary ALI definition 0 - - 0 - - 
Tertiary ALI definition 0 - - 0 - - 
790.4 Nonspecific elevation of transaminase or LDH     
Secondary ALI definition 1 1 100.0  
(2.5-100.0) 
2 0 0.0  
(0.0-84.2) 
Tertiary ALI definition 1 1 100.0  
(2.5-100.0) 
1 0 0.0  
(0.0-97.5) 
789.1 Hepatomegaly        
Secondary ALI definition 0 - - 0 0 - 
Tertiary ALI definition 0 - - 0 0 - 
CI = confidence interval; ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical 
Modification; LDH = lactic acid dehydrogenase; TP = true positives. 
Note: PPVs for the ICPC codes used to define cases for the tertiary ALI definition in EpiChron are presented in 
eTable 5.  
a The number of cases of the secondary ALI definition with specific codes did not necessarily match the 
number of cases for the primary ALI definition because, for example, a case qualifying as a primary ALI 
definition with a specific code could also qualify as a secondary ALI definition with a nonspecific code. If the 
latter scenario happened first, for the secondary ALI definition, this case would be computed in the nonspecific 
codes group rather than in the specific codes group. 
b PPV was calculated as PPV = confirmed cases / (true positives + false positives). Results are presented as 
positive predictive values (%) and their 95% CIs. 
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Table 4. Positive Predictive Values (PPVs) of Specific and Nonspecific Codes 
Used to Identify Potential Acute Liver Injury (ALI) Cases: Secondary (Regular 
Font) and Tertiary (Italics) ALI Definitions in Data Sources Using ICD-10-CM 
Codes (Non-evaluable Cases Not Included) 
 
SIDIAPa Denmarkb 
Total TP 
PPV, % 
(95% CI)c Total TP 
PPV, % 
(95% CI)c 
Specific codes    
K71.0 Toxic liver disease with cholestasis     
Secondary ALI definition    n < 5 n < 5 50.0  
(1.3-98.7) 
Tertiary ALI definition 0 - - 5 n < 5 60.0  
(14.7-94.7) 
K71.1 Toxic liver disease with hepatic necrosis     
Secondary ALI definition    5 n < 5 40.0  
(5.3-85.3) 
Tertiary ALI definition 0 - - 6 n < 5 33.3  
(4.3-77.7) 
K71.2 Toxic liver disease with acute hepatitis     
Secondary ALI definition    9 8 88.9  
(51.8-99.7) 
Tertiary ALI definition 0 - - 13 12 92.3  
(64.0-99.8) 
K71.6 Toxic liver disease with hepatitis, not elsewhere 
classified 
   
Secondary ALI definition    8 7 87.5  
(47.3-99.7) 
Tertiary ALI definition 5 2 40.0  
(5.3-85.3) 
9 8 88.9  
(51.8-99.7) 
K71.9 Toxic liver disease, unspecified      
Secondary ALI definition    5 n < 5 80.0  
(28.4-99.5) 
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SIDIAPa Denmarkb 
Total TP 
PPV, % 
(95% CI)c Total TP 
PPV, % 
(95% CI)c 
Tertiary ALI definition 1 0 0.0  
(0.0-97.5) 
12 6 50.0  
(21.1-78.9) 
K72.0 Acute and subacute 
hepatic failure 
      
Secondary ALI definition    7 6 85.7  
(42.1-99.6) 
Tertiary ALI definition 3 2 66.7  
(9.4-99.2) 
9 8 88.9  
(51.8-99.7) 
K72.9 Hepatic failure, unspecified       
Secondary ALI definition    10 6 60.0  
(26.2-87.8) 
Tertiary ALI definition 8 1 12.5  
(0.3-52.7) 
13 7 53.8  
(25.1-80.8) 
K75.9 Inflammatory liver disease, unspecified     
Secondary ALI definition    n < 5 n < 5 66.7  
(9.4-99.2) 
Tertiary ALI definition 23 7 30.4  
(13.2-52.9) 
5 n < 5 60.0  
(14.7-94.7) 
K76.2 Central hemorrhagic 
necrosis of liver 
      
Secondary ALI definition    n < 5 n < 5 100  
(2.5-100) 
Tertiary ALI definition 0 - - n < 5 n < 5 100  
(2.5-100) 
Nonspecific codes    
K76.8 Other specified diseases of liver     
Secondary ALI definition    16 n < 5 6.3  
(0.2-30.2) 
Tertiary ALI definition 111 1 0.9  
(0.0-4.9) 
35 n < 5 11.4  
(3.2-26.7) 
K76.9 Liver disease, unspecified       
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SIDIAPa Denmarkb 
Total TP 
PPV, % 
(95% CI)c Total TP 
PPV, % 
(95% CI)c 
Secondary ALI definition    30 15 50.0  
(31.3-68.7) 
Tertiary ALI definition 116 11 9.5  
(4.8-16.3) 
107 33 30.8  
(22.3-40.5) 
R17 Unspecified jaundice, excludes neonatal    
Secondary ALI definition    79 75 94.9  
(87.5-98.6) 
Tertiary ALI definition 57 20 35.1  
(22.9-48.9) 
90 82 91.1  
(83.2-96.1) 
R16.0 Hepatomegaly, not elsewhere classified    
Secondary ALI definition    7 n < 5 42.9  
(9.9-81.6) 
Tertiary ALI definition 52 3 5.8  
(1.2-15.9) 
12 n < 5 25.0  
(5.5-57.2) 
R16.2 Hepatomegaly with splenomegaly, not elsewhere 
classified 
   
Secondary ALI definition    n < 5 n < 5 75.0  
(19.4-99.4) 
Tertiary ALI definition 0 - - 6 n < 5 50.0  
(11.8-88.2) 
R74.0 Nonspecific elevation of transaminase and LDH    
Secondary ALI definition    27 16 59.3  
(38.8-77.6) 
Tertiary ALI definition 1,85
2 
119 6.4  
(5.4-7.6) 
120 33 27.5  
(19.7-36.4) 
Z94.4 Liver transplant       
Secondary ALI definition    0 - - 
Tertiary ALI definition 0 - - 0 - - 
CI = confidence interval; ICD-10-CM = International Classification of Diseases, Tenth Revision, Clinical 
Modification; LDH = lactic acid dehydrogenase; TP = true positives. 
a In SIDIAP, ICD-10 codes were used only for the outpatient codes of the study tertiary ALI definition. 
37 
b Due to data protection policies in Denmark, the exact number of cases could not be provided when the 
number of cases was less than five. 
c PPV was calculated as PPV = confirmed cases / (true positives + false positives). Results are presented as 
positive predictive values (%) and their 95% CIs. 
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Figures  
Figure 1. Definition of the Study ALI Definition Algorithmsa  
 
a ALI definition refers to the case-identifying algorithms only. By definition, the secondary ALI definition in the 
analysis included only cases confirmed after validation. 
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Figure 2. Flowchart With the Flow of Potential Cases Through the Case 
Validation Process: Secondary (Regular Font) and Tertiary (Italics) ALI 
Definitions 
40 
a 
Note: In each cell, the first number refers to secondary ALI definitions and the second number refers to tertiary 
ALI definitions. 
41 
Note: One hundred fifteen patients did not undergo further validation due to the lack of additional hospital data 
for those cases. Among them, 3 were classified as true positives, 69 as false positives, and 35 were 
considered non-evaluable during patient profile review. 
b One hundred seven patients identified on ambulatory codes and with lack of additional hospital data were 
directly adjudicated during the patient profile phase. 
c Patients with study exclusion criteria not identified by hospital codes were excluded during the abstraction or 
review of medical records. 
 
